| Market Cap | 1.39B 1.24B 1.16B 1.05B 1.98B 135B 2B 13.93B 5.45B 68.56B 5.23B 5.12B 220B | P/E 2026 * |
-5.05x | P/E 2027 * | -3.98x |
|---|---|---|---|---|---|
| Enterprise Value | 1.31B 1.17B 1.09B 988M 1.86B 126B 1.88B 13.05B 5.11B 64.23B 4.9B 4.79B 207B | EV / Sales 2026 * |
31.2x | EV / Sales 2027 * | 20.7x |
| Free-Float |
99.62% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Nektar Therapeutics
| 1 day | -0.71% |
| Manager | Title | Age | Since |
|---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 73 | 01/01/2007 |
Linda Rubinstein
DFI | Director of Finance/CFO | 60 | 15/05/2026 |
| Chief Tech/Sci/R&D Officer | 52 | 01/07/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Roy Whitfield
BRD | Director/Board Member | 72 | 01/08/2000 |
Robert Chess
CHM | Chairman | 69 | 01/05/1992 |
Howard Robin
BRD | Director/Board Member | 73 | 01/02/2007 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.71% | +1.97% | - | - | 1.37B | |
| -3.19% | -3.19% | +44.60% | +87.98% | 74.68B | |
| -15.86% | -16.16% | +2.68% | +50.90% | 58.7B | |
| -2.39% | +0.50% | +3.41% | +31.33% | 48.36B | |
| -6.35% | -8.63% | +293.39% | +651.28% | 43.05B | |
| +0.30% | -0.71% | +29.05% | +30.33% | 42.48B | |
| -3.82% | -2.41% | -0.27% | +101.36% | 41.39B | |
| -2.13% | -2.18% | +7.51% | +50.31% | 31.29B | |
| -3.35% | -4.95% | -13.38% | -17.22% | 23.93B | |
| -5.27% | +1.86% | +12.19% | -5.34% | 22.24B | |
| Average | -4.28% | -3.20% | +42.13% | +108.99% | 42.9B | |
| Weighted average by Cap. | -5.08% | -3.89% | +45.82% | +118.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 41.88M 37.4M 34.89M 31.69M 59.63M 4.06B 60.22M 419M 164M 2.06B 157M 154M 6.63B | 57M 50.9M 47.48M 43.13M 81.16M 5.52B 81.96M 570M 223M 2.81B 214M 209M 9.02B |
| Net income | -245M -218M -204M -185M -348M -23.7B -352M -2.45B -957M -12.04B -919M -899M -38.73B | -354M -316M -295M -268M -504M -34.26B -509M -3.54B -1.38B -17.41B -1.33B -1.3B -55.99B |
| Net Debt | -88.02M -78.6M -73.33M -66.61M -125M -8.52B -127M -880M -344M -4.33B -330M -323M -13.93B | -210M -188M -175M -159M -300M -20.37B -302M -2.1B -823M -10.35B -790M -773M -33.3B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
